DEEP PHARMA INTELLIGENCE

Deep Pharma Intelligence

Artificial Intelligence for Nuclear Medicine Q1 2023

About Deep Pharma Intelligence

Deep Pharma Intelligence (DPI) is a leading UK-based strategic and investment intelligence agency focused on the emerging markets in the Pharmaceutical, Biotech, and Healthcare Tech industries.

Deep Pharma Intelligence is a joint venture created by **Deep Knowledge Analytics Pharma Division** and **BPT Analytics (BiopharmaTrend)** -- two highly specialized think tanks in the area of biotech innovation profiling, business intelligence, and biotech investment advisory. The company is dedicated to producing powerful data mining and visualization systems, interactive analytics tools, and industry reports offering deep technical insights, business intelligence, and strategic guidance in the high growth and significant opportunity areas of the pharmaceutical industry, including artificial intelligence (AI) in drug discovery, emerging therapeutic targets and drug modalities, new therapies and technologies, promising startups, and more.

Our Value Proposition:

Open Access and Proprietary Reports

Deep Pharma Intelligence is producing regular open access reports covering emerging bio-pharmaceutical markets -- technologies, innovations, companies, and trends.

Our clients and partners can enjoy access to proprietary reports, featuring additional in-depth research conducted by our team on regular basis.

IT-Platform and Big Data Analytics Dashboard

Our company is building a sophisticated cloud-based engine for advanced market and business intelligence in the pharmaceutical and healthcare industries. It includes data mining engine, infrastructure for expert data curation, and advanced visualization dashboards, including mindmaps, knowledge graphs, and 3-dimensional visualizations.

Visit our dashboard to learn more:
platform.dkv.global/dashboards/ai-for-drug-discovery

Strategic Consulting and Investment Advisory

Deep Pharma Intelligence offers a comprehensive range of consulting services, including comprehensive support for growth and investment decision making in the bio-pharmaceutical industry and related areas. It includes a wide range of services from market and competitor research, technology scouting and due diligence, to investment landscape profiling and comprehensive analytics support for investment decision-making.

Artificial Intelligence for Nuclear Medicine Q1 2023

This 85-page "Artificial Intelligence in Nuclear Medicine Q1 2023" report aims to provide a comprehensive overview of the industry landscape in what pertains adoption of AI in image processing, clinical research and other aspects of radiology and nuclear medicine R&D. This overview highlights trends and insights in a form of informative mind maps and infographics as well as benchmarks the performance of key players that form the space and relations within the industry.

Together **DPI**, **The Yuan** and **Evomics Medical** highlighted 155 leading AI Nuclear Medicine companies industry developments, case studies, and trends in the following 4 categories:

- **Planning and optimisation**
- **Scanning and image reconstruction**
- **Data interpretation**
- **Reporting and clinical decision support**

The aim of this report is to provide insights to corporate executives, technology scouts, and deep tech investors about where the industry is heading, and where opportunities emerge.

Some of the key takeaways from this digest include:

- Pharmaceutical AI sector is "heating up" for investments.
- The prominent rise of AI application in Nuclear Medicine was in 2021 (3X more clinical trials than in 2020)
- COVID-19 pandemics appears to be a positive catalyst for the acceleration of the AI adoption.
- Companies that develop AI for Nuclear Medicine can be divided into three categories: international pharmaceutical companies, technological companies, and startup companies.
- One of the key drivers for the nuclear medicine imaging market growth is Increased knowledge of the potential impact of early and prompt diagnosis.

DEEP PHARMA INTELLIGENCE

Deep Pharma Intelligence

Artificial Intelligence in Nuclear Medicine

Q1 2023

Landscape of AI in Nuclear Medicine Companies



Regional Trends of AI Applications in Nuclear Medicine